In RNA-seq data from B-ALL patients who lost surface CD19 following CD19 CAR-T therapy [2], post-therapy samples showed increased LILRB1 mRNA levels, while CD22 and MS4A1 (codes for CD20) levels were reduced (Fig. 4C). Here, LILRB1 is linked to precursor B-cell acute lymphoblastic leukemia.